药械

订阅

MedSci主页 / 所有栏目 / 药械

全球上市BCL-2抑制剂维奈克拉在华获批

2020-12-07 网络 网络

维奈克拉
关注

1月13日，艾伯维Bcl-2选择性抑制剂维奈克拉（Venetoclax）国内申报上市，维奈克拉是目前全球唯一获批上市的基于细胞凋亡机制开发的细胞凋亡药物。维奈克拉是目前全球唯一获批上市的Bcl-2选择

1月13日，艾伯维Bcl-2选择性抑制剂维奈克拉（Venetoclax）国内申报上市，维奈克拉是目前全球唯一获批上市的基于细胞凋亡机制开发的细胞凋亡药物。维奈克拉是目前全球唯一获批上市的Bcl-2选择性抑制剂，通过抑制凋亡Bcl-2达到促进CLL细胞凋亡的目的。Bcl-2是一类负责调节细胞凋亡的基因家族，在维持细胞存活以及抑制细胞凋亡中发挥着重要作用。

Bcl-2家族可以分为两大类，一类是抗凋亡的，主要有Bcl-2、Bcl-xL、Bcl-W、Mcl-1、CED9等，另一类是促细胞死亡的，主要包括Bax、Bak、Bcl-XS、Bad、Bik、Bid等。其中，Bcl-2、Bcl-xL和Mcl-1主要位于线粒体外膜，负责调控凋亡级联反应中的重要信号分子细胞色素C（Cytc）以及SMAC的释放。释放的细胞色素C能够促进细胞凋亡，SMAC能够通过抑制IAP来促进细胞凋亡。Bcl-2基因突变是多种癌症发生的主要原因，当Bcl-2中抗凋亡基因过表达会阻止细胞色素C及SMAC释放，从而抑制细胞凋亡导致癌症的发生。

维奈克拉(维奈托克)全球价格2020年4月采集

维奈克拉由艾伯维研发，于2015年被FDA授予突破性治疗，2016年获FDA批准上市，用于治疗慢性淋巴细胞性白血病（CLL）或小淋巴细胞性淋巴瘤（SLL）。目前venetoclax正在进行的临床试验超过80个，根据其一线试验结果，维奈克拉未来数年内或将成为治疗CLL的一线药物。据艾伯维公司财报显示，2018年以及2019年H1，维奈克拉分别取得了3.4亿美元、3.2亿美元，预计2019年全年增长超100%。

国家药监局官网信息显示，艾伯维与罗氏共同开发的BCL-2抑制剂维奈克拉片已经在中国获批上市。其适应症为与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病（AML）患者。

数据显示，该药2016年在美国获批，是全球首个BCL-2抑制剂。2020年前三季度的销售额9.72亿美元，年销售额将超过10亿美元，有望成为上述公司的重磅产品。

相关报道：

Venclyxto（venetoclax）治疗慢性淋巴细胞性白血病：已获NICE支持

NEJM：Venetoclax治疗急性髓性白血病（AML），III期临床取得正面结果

Blood：BTK抑制剂疗法可有效治疗venetoclax耐药性CLL

Lancet Haematol：Venetoclax联合地西他滨10日疗法治疗各种AML亚型的疗效

Blood：决定AML老年患者经venetoclax联合化疗预后的分子特征！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1067283, encodeId=be38106e28387, content=希望能起到更好的治疗效果, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04085693184, createdName=ms1000001940293226, createdTime=Fri Nov 05 14:18:04 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852557, encodeId=f8e9185255ea0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 11 05:09:49 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995622, encodeId=3d4d199562271, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Oct 29 18:09:49 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634992, encodeId=46a216349924a, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Thu Jul 15 07:09:49 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707335, encodeId=fc211e07335f3, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Fri Jun 18 09:09:49 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912473, encodeId=a2219124e37b, content=这次和海外上市只隔了短短几年, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fbc25397442, createdName=ms1000000374543602, createdTime=Thu Dec 31 09:31:36 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906012, encodeId=f66690601265, content=希望这款新药可以让更多的患者获益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Tue Dec 08 15:03:52 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905821, encodeId=0181905821c6, content=可以让更多患者获益了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Dec 07 22:11:42 CST 2020, time=2020-12-07, status=1, ipAttribution=)]
    2021-11-05 ms1000001940293226

    希望能起到更好的治疗效果

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1067283, encodeId=be38106e28387, content=希望能起到更好的治疗效果, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04085693184, createdName=ms1000001940293226, createdTime=Fri Nov 05 14:18:04 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852557, encodeId=f8e9185255ea0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 11 05:09:49 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995622, encodeId=3d4d199562271, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Oct 29 18:09:49 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634992, encodeId=46a216349924a, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Thu Jul 15 07:09:49 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707335, encodeId=fc211e07335f3, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Fri Jun 18 09:09:49 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912473, encodeId=a2219124e37b, content=这次和海外上市只隔了短短几年, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fbc25397442, createdName=ms1000000374543602, createdTime=Thu Dec 31 09:31:36 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906012, encodeId=f66690601265, content=希望这款新药可以让更多的患者获益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Tue Dec 08 15:03:52 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905821, encodeId=0181905821c6, content=可以让更多患者获益了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Dec 07 22:11:42 CST 2020, time=2020-12-07, status=1, ipAttribution=)]
    2021-02-11 jklm09

    #抑制剂#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1067283, encodeId=be38106e28387, content=希望能起到更好的治疗效果, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04085693184, createdName=ms1000001940293226, createdTime=Fri Nov 05 14:18:04 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852557, encodeId=f8e9185255ea0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 11 05:09:49 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995622, encodeId=3d4d199562271, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Oct 29 18:09:49 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634992, encodeId=46a216349924a, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Thu Jul 15 07:09:49 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707335, encodeId=fc211e07335f3, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Fri Jun 18 09:09:49 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912473, encodeId=a2219124e37b, content=这次和海外上市只隔了短短几年, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fbc25397442, createdName=ms1000000374543602, createdTime=Thu Dec 31 09:31:36 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906012, encodeId=f66690601265, content=希望这款新药可以让更多的患者获益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Tue Dec 08 15:03:52 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905821, encodeId=0181905821c6, content=可以让更多患者获益了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Dec 07 22:11:42 CST 2020, time=2020-12-07, status=1, ipAttribution=)]
    2021-10-29 爆笑小医

    #2抑制剂#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1067283, encodeId=be38106e28387, content=希望能起到更好的治疗效果, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04085693184, createdName=ms1000001940293226, createdTime=Fri Nov 05 14:18:04 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852557, encodeId=f8e9185255ea0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 11 05:09:49 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995622, encodeId=3d4d199562271, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Oct 29 18:09:49 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634992, encodeId=46a216349924a, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Thu Jul 15 07:09:49 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707335, encodeId=fc211e07335f3, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Fri Jun 18 09:09:49 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912473, encodeId=a2219124e37b, content=这次和海外上市只隔了短短几年, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fbc25397442, createdName=ms1000000374543602, createdTime=Thu Dec 31 09:31:36 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906012, encodeId=f66690601265, content=希望这款新药可以让更多的患者获益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Tue Dec 08 15:03:52 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905821, encodeId=0181905821c6, content=可以让更多患者获益了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Dec 07 22:11:42 CST 2020, time=2020-12-07, status=1, ipAttribution=)]
    2021-07-15 ms3153534357578991

    #BCL-2抑制剂#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1067283, encodeId=be38106e28387, content=希望能起到更好的治疗效果, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04085693184, createdName=ms1000001940293226, createdTime=Fri Nov 05 14:18:04 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852557, encodeId=f8e9185255ea0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 11 05:09:49 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995622, encodeId=3d4d199562271, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Oct 29 18:09:49 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634992, encodeId=46a216349924a, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Thu Jul 15 07:09:49 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707335, encodeId=fc211e07335f3, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Fri Jun 18 09:09:49 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912473, encodeId=a2219124e37b, content=这次和海外上市只隔了短短几年, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fbc25397442, createdName=ms1000000374543602, createdTime=Thu Dec 31 09:31:36 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906012, encodeId=f66690601265, content=希望这款新药可以让更多的患者获益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Tue Dec 08 15:03:52 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905821, encodeId=0181905821c6, content=可以让更多患者获益了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Dec 07 22:11:42 CST 2020, time=2020-12-07, status=1, ipAttribution=)]
    2021-06-18 ms3323097325231039

    #BCL-2#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1067283, encodeId=be38106e28387, content=希望能起到更好的治疗效果, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04085693184, createdName=ms1000001940293226, createdTime=Fri Nov 05 14:18:04 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852557, encodeId=f8e9185255ea0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 11 05:09:49 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995622, encodeId=3d4d199562271, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Oct 29 18:09:49 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634992, encodeId=46a216349924a, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Thu Jul 15 07:09:49 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707335, encodeId=fc211e07335f3, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Fri Jun 18 09:09:49 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912473, encodeId=a2219124e37b, content=这次和海外上市只隔了短短几年, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fbc25397442, createdName=ms1000000374543602, createdTime=Thu Dec 31 09:31:36 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906012, encodeId=f66690601265, content=希望这款新药可以让更多的患者获益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Tue Dec 08 15:03:52 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905821, encodeId=0181905821c6, content=可以让更多患者获益了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Dec 07 22:11:42 CST 2020, time=2020-12-07, status=1, ipAttribution=)]
    2020-12-31 ms1000000374543602

    这次和海外上市只隔了短短几年

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1067283, encodeId=be38106e28387, content=希望能起到更好的治疗效果, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04085693184, createdName=ms1000001940293226, createdTime=Fri Nov 05 14:18:04 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852557, encodeId=f8e9185255ea0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 11 05:09:49 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995622, encodeId=3d4d199562271, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Oct 29 18:09:49 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634992, encodeId=46a216349924a, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Thu Jul 15 07:09:49 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707335, encodeId=fc211e07335f3, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Fri Jun 18 09:09:49 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912473, encodeId=a2219124e37b, content=这次和海外上市只隔了短短几年, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fbc25397442, createdName=ms1000000374543602, createdTime=Thu Dec 31 09:31:36 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906012, encodeId=f66690601265, content=希望这款新药可以让更多的患者获益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Tue Dec 08 15:03:52 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905821, encodeId=0181905821c6, content=可以让更多患者获益了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Dec 07 22:11:42 CST 2020, time=2020-12-07, status=1, ipAttribution=)]
    2020-12-08 Jessie Zhang

    希望这款新药可以让更多的患者获益。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1067283, encodeId=be38106e28387, content=希望能起到更好的治疗效果, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04085693184, createdName=ms1000001940293226, createdTime=Fri Nov 05 14:18:04 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852557, encodeId=f8e9185255ea0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 11 05:09:49 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995622, encodeId=3d4d199562271, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Oct 29 18:09:49 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634992, encodeId=46a216349924a, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Thu Jul 15 07:09:49 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707335, encodeId=fc211e07335f3, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Fri Jun 18 09:09:49 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912473, encodeId=a2219124e37b, content=这次和海外上市只隔了短短几年, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fbc25397442, createdName=ms1000000374543602, createdTime=Thu Dec 31 09:31:36 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906012, encodeId=f66690601265, content=希望这款新药可以让更多的患者获益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Tue Dec 08 15:03:52 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905821, encodeId=0181905821c6, content=可以让更多患者获益了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Dec 07 22:11:42 CST 2020, time=2020-12-07, status=1, ipAttribution=)]
    2020-12-07 lovetcm

    可以让更多患者获益了

    0